nmk89
Pancreatic Cancer
Nihon Medi-Physics Co., Ltd.radiopharmaceuticalPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 59/ 100
Competitive context
381 Active assets in the Pancreatic Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tinzaparin Helsinki University Central Hospital | Phase 4 | BBB |
FLUOROURACILUM Memorial Sloan Kettering Cancer Center | Phase 3 | BB |
Eloxatin Memorial Sloan Kettering Cancer Center | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Taiho Oncology, Inc. | Phase 3 | BB |
Irinotecan Memorial Sloan Kettering Cancer Center | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →